AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27711088
Drug: Counseling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling and sexual behavioral treatment (Control Group B)
Trial: 363229
Drug: Azathioprine plus
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine plus prednisone (2.5 mg/kg body weight daily)
Trial: 31539169
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) - 6 weekly 2-hour group sessions
Trial: 31539169
Drug: Survivorship Education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survivorship Education (SE) - 6 weekly 2-hour group sessions
Trial: 25091596
Drug: Dialysate potassium
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate potassium concentration between 1.6 and 2.5 mEq/L
Trial: 21197586
Drug: high fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high fat load (50 g fat)
Trial: 16544256
Drug: ACT (Artemisinin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT (Artemisinin-based combination therapy)
Trial: 10902643
Drug: Combination antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral therapy (HAART)
Trial: 8317753
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia using isolated forearm technique with intravenous thiopental (3 mg/kg, 250 mg maximum) and succinylcholine (1.5 mg/kg), followed by a mixture of 50% N2O, 50% O2, and 0.5% halothane at a flow of 5 L/min and end‐tidal CO2 at 40 mm Hg. Paralysis maintained with a 0.1% succinylcholine infusion.
Trial: 2427405
Drug: Anabolic steroids
RxNorm normalized name: ANABOLIC STEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anabolic steroids plus phenformin
Trial: 20209200
Drug: One implant
RxNorm normalized name: Testosterone Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One implant in the symphyseal area
Trial: 20209200
Drug: Two implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two implants in the canine positions
Trial: 18665190
Drug: ACE (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE (doxorubicin 50 mg/m(2) i.v., cyclophosphamide 1 g/m(2) i.v., etoposide 120 mg/m(2) i.v. on day 1, etoposide 240 mg/m(2) orally for 2 days)
Trial: 18665190
Drug: PE (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE (cisplatin 80 mg/m(2) and etoposide 120 mg/m(2) i.v. on day 1, etoposide 240 mg/m(2) orally for 2 days)
Trial: 6190545
Drug: Methotrexate (MTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX), 40 mg escalated to 60 mg/m2 IV push weekly
Trial: 6190545
Drug: Cisplatin (DDP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (DDP), 50 mg/m2 6 hour infusion days 1 and 8 every 4 weeks
Trial: 30624856
Drug: Rolapitant tablet
DrugBank: Rolapitant (DB09291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rolapitant tablet (2 × 90-mg tablets)
Trial: 30624856
Drug: Rolapitant capsule
DrugBank: Rolapitant (DB09291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rolapitant capsule (4 × 45-mg capsules)
Trial: 30624856
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (tablet and capsule)
Trial: 29878040
Drug: nab-Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-Paclitaxel plus gemcitabine (nab-P/G)
Trial: 29878040
Drug: gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine plus carboplatin (G/C)
Trial: 26951105
Drug: Algorithm-guided goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-guided goal-directed haemodynamic therapy (GDT)
Trial: 8312045
Drug: Letter from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letter from general practitioner plus four information sheets at monthly intervals.
Trial: 2455011
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus radiotherapy (group I)
Trial: 2455011
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (group II)
Trial: 26652592
Drug: Concurrent anxiety
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent anxiety and/or depression
Trial: 23422921
Drug: Oat or
RxNorm normalized name: Therabloat Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat or barley products providing 0.3-12.1 g β-glucan
Trial: 23422921
Drug: Processed foods
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Processed foods containing 4 g of β-glucan
Trial: 12935409
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural blockade (TEB) with 0.5% lidocaine 3-5 ml every 2-4 hours for four weeks
Trial: 12935409
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine medicine only)
Trial: 3940792
Drug: Inhaled atropine
RxNorm normalized name: atropine sulfate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled atropine sulfate (0.075 mg/kg)
Trial: 15649652
Drug: 450 ml
RxNorm normalized name: ALCOHOL 270 mL in 450 mL EXTRACORPOREAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 ml of black tea (acute)
Trial: 15649652
Drug: 900 ml
RxNorm normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 ml of black tea per day (chronic)
Trial: 16259812
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg oestradiol patches (Evorel) used during the pill-free interval for two cycles
Trial: 16259812
Drug: Placebo used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo used during the pill-free interval for two cycles
Trial: 9558519
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser treatment at apical and radicular portions
Trial: 9558519
Drug: Ultrasonic device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic device for retrograde cavity preparation
Trial: 9558519
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser treatment at apical and radicular portions instead of micro bur
Trial: 7625112
Drug: DTPwHBV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPwHBV vaccine administered in three doses (2 months apart)
Trial: 2152973
Drug: High-fiber oat
RxNorm normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber oat bran (87 g per day)
Trial: 31740429
Drug: Home-based family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based family-based weight loss treatment
Trial: 31740429
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care family-based weight loss treatment delivered in an academic medical center
Trial: 28949281
Drug: Activity-based mirror
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity-based mirror therapy (MT)
Trial: 28605294
Drug: CryJ2-LAMP DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CryJ2-LAMP DNA vaccine (4 doses of 4mg/1ml for non-sensitive subjects and 4 doses of 2mg/0.5ml for sensitive subjects)
Trial: 28605294
Drug: CryJ2-LAMP DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CryJ2-LAMP DNA vaccine (1 booster dose of 2mg/0.5ml)
Trial: 28605294
Drug: CryJ2-LAMP DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CryJ2-LAMP DNA vaccine
Trial: 25214645
Drug: Standard Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Behavioral Treatment + Enhanced Parenting (SBT + EP)
Trial: 24601050
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 10 mg for 10 days during a month for three months
Trial: 21390898
Drug: Self-administered computerized
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered computerized version of TOMM
Trial: 21390898
Drug: Examiner-administered booklet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Examiner-administered booklet version of TOMM
Trial: 1683301
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg levonorgestrel tablets (two types)
Trial: 15069173
Drug: Low-calcium dialysate
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calcium dialysate (LCD; calcium: 1.25 mmol/l)
Trial: 15069173
Drug: Standard calcium
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard calcium dialysate (SCD; calcium: 1.75 mmol/l)
Trial: 7939388
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with coronary heart disease, rectal cancer, and multiple sclerosis
Trial: 2526993
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose omega-3 fatty acid (N3FA) supplementation (4.5 g/day)
Trial: 2526993
Drug: N3FA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N3FA supplementation (4.5 g/day)
Trial: 31634905
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (4 g; n=415)
Trial: 28736559
Drug: Levocarnitine injections
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocarnitine injections (1,000 mg 3 times weekly after hemodialysis)
Trial: 28736559
Drug: Levocarnitine injections
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocarnitine injections
Trial: 20007408
Drug: Alpha-adrenergic blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-adrenergic blocking drug
Trial: 15630469
Drug: three successive
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three successive fixed therapy interruptions (TIs) of 2, 4, and 6 weeks, with intervening resumption of therapy for 4 weeks before subsequent interruption
Trial: 15630469
Drug: 40 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 weeks of continuous therapy
Trial: 9222086
Drug: ET-1 (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-1 (0 (saline), 1.25, 2.5 and 5.0 ng/kg/min; 20 minutes per dose)
Trial: 3819261
Drug: Dihydroergotoxine mesylate
RxNorm normalized name: Dihydroergotoxine mesylate
DrugBank: Dihydroergotoxine (DB16602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotoxine mesylate (DEM, Hydergine) at 6 mg per day, administered orally for 12 weeks
Trial: 31728731
Drug: Desensitizing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizing agents (Vertise Flow, Universal Dentin Sealant, Clearfil Protect Bond, Flor‐Opal Varnish)
Trial: 27989253
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry concentrate (60 ml dose)
Trial: 24048913
Drug: Tapering group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering group (G2) - performed reduced training volume (3 sets/exercise; -22%)
Trial: 23737453
Drug: Almorexant 200
RxNorm normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Almorexant 200 mg once daily for 10 days with warfarin 25 mg on day 5
Trial: 23737453
Drug: Warfarin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 25 mg on day 1
Trial: 20502393
Drug: Patient-delivered partner
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-delivered partner treatment (PDPT) with metronidazole
Trial: 18443798
Drug: Early detection
RxNorm normalized name: Leader Early Detection Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early detection and treatment of amblyopia; specific intervention details not available.
Trial: 12819517
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) for nelfinavir
Trial: 12819517
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) for indinavir
Trial: 12819517
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) for both drugs
Trial: 12819517
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no TDM) for both drugs
Trial: 10099058
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg once daily (clinical dosage)
Trial: 10099058
Drug: Montelukast 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 600 mg (200 mg three times daily)
Trial: 28118425
Drug: Lidocaine injections
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injections
Trial: 25088520
Drug: combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined treatment
Trial: 17117182
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV 6/11/16/18 L1 virus-like particle vaccine
Trial: 16929590
Drug: Silybum marianum
RxNorm normalized name: Silybum marianum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silybum marianum 160 mg orally three times a week for four weeks
Trial: 28589965
Drug: No-treatment (control)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment (control)
Trial: 11336929
Drug: Verteporfin therapy
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin therapy (6 mg per square meter of body surface area) administered by intravenous infusion over 10 minutes, followed by laser treatment at 689 nm.
Trial: 11336929
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (5% dextrose in water) administered by intravenous infusion over 10 minutes, followed by sham laser treatment.
Trial: 3304409
Drug: Routine postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine postoperative therapy alone
Trial: 31486230
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of canagliflozin (100 mg/d) and teneligliptin (20 mg/d)
Trial: 31486230
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor monotherapy (canagliflozin 100 mg/d)
Trial: 31198139
Drug: CPIS-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPIS-guided therapy
Trial: 26686794
Drug: Cinacalcet in
RxNorm normalized name: Product containing cinacalcet in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet in addition to conventional therapy
Trial: 19542983
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg/day
Trial: 8325041
Drug: Rifaximin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (1200 mg/day for 15 days)
Trial: 8325041
Drug: Lactulose (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (30 g/day for 15 days)
Trial: 3090597
Drug: 0.347 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.347 g/kg ethanol
Trial: 3090597
Drug: 0.694 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.694 g/kg ethanol
Trial: 29226494
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) for problem gambling
Trial: 29226494
Drug: Routine CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine CBT treatments
Trial: 29226494
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy for problem gambling
Trial: 11414348
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for alcohol and drug abuse
Trial: 7826557
Drug: Low-sodium/high-potassium diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium/high-potassium diet with chlorthalidone (25 mg/day)
Trial: 7826557
Drug: Low-sodium/high-potassium diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium/high-potassium diet with atenolol (50 mg/day)
Trial: 7826557
Drug: Usual diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual diet with chlorthalidone (25 mg/day)
Trial: 7826557
Drug: Usual diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual diet with atenolol (50 mg/day)
Trial: 3279101
Drug: Intravenous nutrient
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous nutrient infusion containing amino acids (3.4 g/h), dextrose (20 g/h), and insulin (1.6 units/h)
Trial: 3279101
Drug: Intravenous nutrient
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous nutrient infusion containing amino acids, glucose, and insulin
Trial: 22891287
Drug: Intramuscular route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular route of subvirion inactivated influenza A virus subtype H5N1 vaccine (38.7 μg of H5N1 hemagglutinin)
Trial: 22891287
Drug: Intradermal route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal route of subvirion inactivated influenza A virus subtype H5N1 vaccine (38.7 μg of H5N1 hemagglutinin)
Trial: 17483649
Drug: Oral risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral risedronate 5 mg/day after the fifth postoperative day
Trial: 10475183
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of a sun protection factor 15-plus sunscreen
Trial: 10475183
Drug: Betacarotene supplementation
RxNorm normalized name: betacarotene
DrugBank: Beta carotene (DB06755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betacarotene supplementation (30 mg per day)
Trial: 10475183
Drug: Sunscreen plus
RxNorm normalized name: Sunmark Sunscreen Plus E and Aloe SPF 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen plus placebo tablets
Trial: 25830400
Drug: Implant-supported fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported fixed partial dentures (IFPDs)
Trial: 22057411
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment based on identified CM patterns
Trial: 18723297
Drug: Dose-escalated three-dimensional
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated three-dimensional conformal radiotherapy (3D-CRT) at doses of 66, 72, 78, and 84 Gy with concurrent Carmustine 80 mg/m² during RT and every 8 weeks for 6 cycles
Trial: 17327934
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg
Trial: 7220406
Drug: Erythromycin estolate
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate preparation (500 mg)
Trial: 7220406
Drug: Erythromycin propionate
RxNorm normalized name: erythromycin propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin propionate preparation (500 mg)
Trial: 7220406
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate preparation (500 mg)
Trial: 23065731
Drug: Referral strategy
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral strategy 2 (two of the following: IBP, HLA‐B27, sacroiliitis, family history of axial SpA, good response to non‐steroidal anti‐inflammatory drugs, extra‐articular manifestations)
Trial: 10879638
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fortified tobramycin (1.5%) and cefazolin (5%) solutions
Trial: 27038225
Drug: p-synephrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-synephrine (3 mg kg(-1))